parkinsons
- Home
- parkinsons
Public
Opening a new frontier in treating Parkinson’s disease
- Review
- November 11, 2022
Is this the most hated company on the ASX?
- Review
- August 16, 2019
Latest Articles
First patients dosed in Phase 2 clinical trials to tackle Parkinson’s disease
Parkinson’s UK, in collaboration with Australian researchers, has taken a major step towards preventing the development of Parkinson’s disease with the first Australian patient in a Phase 2 clinical trial having been dosed with PXS-4708, a novel drug aimed at tackling Parkinson’s before its onset, along with other neurodegenerative disorders. The multi-national trial was initiated
Read MorePublic
Opening a new frontier in treating Parkinson’s disease
More than 100,000 people in Australia live with Parkinson’s—a central nervous system disorder affecting one’s movement and mood. It is a progressive disorder which currently has no cure and few treatments. However, researchers at Parkinson’s UK have a new reason to hope. They are investigating whether early detection and treatment of certain sleeping disorders might
Read MorePublic
Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial
This morning’s announcement may have surprised many investors following the Pharmaxis (ASX: PXS) story because where on earth does Parkinson’s fit into the equation alongside cancer, skin scarring and cystic fibrosis? Unpacking the Pharmaxis investment case reveals an agile company with more than one trick up their sleeves, keeping business buoyant whilst other biotechs list
Read MorePublic
Alterity Therapeutics moves neuroprotective drug to Phase 2 trials
Seven to ten years. That’s how long someone diagnosed with multiple system atrophy (MSA) has to live from when symptoms first appear. The progressive disease results in the gradual functional decline of the body’s involuntary functions such as blood pressure, breathing, bladder function and motor control. Often confused with Parkinson’s which is characterised by the
Read MorePublic
